The evolutionary histories of antiretroviral proteins SERINC3 and SERINC5 do not support an evolutionary arms race in primates

Journal of Virology

Volumn 90, Issue 18, 2016, Pages 8085-8089

  Murrell, Ben ^a   Vollbrecht, Thomas ^a,b   Guatelli, John ^a,b   Wertheim, Joel O ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MEMBRANE PROTEIN; SERINC3 PROTEIN; SERINC5 PROTEIN; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; IMMUNOGLOBULIN RECEPTOR; MEMBRANE PROTEIN; SERINC3 PROTEIN, HUMAN; SERINC5 PROTEIN, HUMAN; TUMOR PROTEIN;

ARTICLE; CONTROLLED STUDY; GENE; GENE FUNCTION; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR DYNAMICS; MOLECULAR EVOLUTION; PRIMATE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; RETROVIRIDAE; SERINC3 GENE; SERINC5 GENE; ANIMAL; GENETICS; HUMAN; IMMUNOLOGY;

ANIMALS; EVOLUTION, MOLECULAR; HUMANS; MEMBRANE PROTEINS; NEOPLASM PROTEINS; PRIMATES; RECEPTORS, CELL SURFACE; RECEPTORS, IMMUNOLOGIC; RETROVIRIDAE;

EID: 84984633192     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00972-16     Document Type: Article

References (37)

1. Van Valen L. 1973. A new evolutionary law. Evol Theory 1:1-30.
2. Enard D, Cai L, Gwennap C, Petrov DA. 2016. Viruses are a dominant driver of protein adaptation in mammals. eLife 5:e12469. http://dx.doi.org/10.7554/eLife.12469.
3. Worobey M, Bjork A, Wertheim JO. 2007. Point, counterpoint: the evolution of pathogenic viruses and their human hosts. Annu Rev Ecol Evol Systematics 38:515-540. http://dx.doi.org/10.1146/annurev.ecolsys.38.091206.095722.
4. Marin M, Rose KM, Kozak SL, Kabat D. 2003. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 9:1398-1403. http://dx.doi.org/10.1038/nm946.
5. Sheehy AM, Gaddis NC, Choi JD, Malim MH. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650. http://dx.doi.org/10.1038/nature00939.
6. Sheehy AM, Gaddis NC, Malim MH. 2003. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 9:1404-1407. http://dx.doi.org/10.1038/nm945.
7. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF. 2003. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302:1056-1060. http://dx.doi.org/10.1126/science.1089591.
8. Song B. 2009. TRIM5alpha. Curr Top Microbiol Immunol 339:47-66.
9. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. 2004. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427:848-853. http://dx.doi.org /10.1038/nature02343.
10. Towers GJ, Hatziioannou T, Cowan S, Goff SP, Luban J, Bieniasz PD. 2003. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat Med 9:1138-1143. http://dx.doi.org/10.1038/nm910.
11. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segeral E, Yatim A, Emiliani S, Schwartz O, Benkirane M. 2011. SAMHD1 is the dendritic-and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 474:654-657. http://dx.doi.org/10.1038/nature10117.
12. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, Florens L, Washburn MP, Skowronski J. 2011. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 474:658-661. http://dx.doi.org/10.1038/nature10195.
13. Evans DT, Serra-Moreno R, Singh RK, Guatelli JC. 2010. BST-2/ tetherin: a new component of the innate immune response to enveloped viruses. Trends Microbiol 18:388-396. http://dx.doi.org/10.1016/j.tim.2010.06.010.
14. Neil SJ, Zang T, Bieniasz PD. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451:425-430. http://dx.doi.org /10.1038/nature06553.
15. Tokarev A, Skasko M, Fitzpatrick K, Guatelli J. 2009. Antiviral activity of the interferon-induced cellular protein BST-2/tetherin. AIDS Res Hum Retroviruses 25:1197-1210. http://dx.doi.org/10.1089/aid.2009.0253.
16. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC, Stephens EB, Guatelli J. 2008. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3:245-252. http://dx.doi.org /10.1016/j.chom.2008.03.001.
17. Daugherty MD, Malik HS. 2012. Rules of engagement: molecular insights from host-virus arms races. Annu Rev Genet 46:677-700. http://dx.doi.org/10.1146/annurev-genet-110711-155522.
18. Duggal NK, Emerman M. 2012. Evolutionary conflicts between viruses and restriction factors shape immunity. Nat Rev Immunol 12:687-695. http://dx.doi.org/10.1038/nri3295.
19. Bogerd HP, Doehle BP, Wiegand HL, Cullen BR. 2004. A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc Natl Acad Sci U S A 101:3770-3774. http://dx.doi.org/10.1073/pnas.0307713101.
20. Kirmaier A, Wu F, Newman RM, Hall LR, Morgan JS, O'Connor S, Marx PA, Meythaler M, Goldstein S, Buckler-White A, Kaur A, Hirsch VM, Johnson WE. 2010. TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species. PLoS Biol 8:e1000462. http://dx.doi.org/10.1371/journal.pbio.1000462.
21. Mangeat B, Turelli P, Liao S, Trono D. 2004. A single amino acid determinant governs the species-specific sensitivity ofAPOBEC3Gto Vif action. J Biol Chem 279:14481-14483. http://dx.doi.org/10.1074/jbc.C400060200.
22. Schrofelbauer B, Chen D, Landau NR. 2004. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc Natl Acad Sci U S A 101:3927-3932. http://dx.doi.org /10.1073/pnas.0307132101.
23. Yap MW, Nisole S, Stoye JP. 2005. A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr Biol 15:73-78. http://dx.doi.org/10.1016/j.cub.2004.12.042.
24. Laguette N, Rahm N, Sobhian B, Chable-Bessia C, Munch J, Snoeck J, Sauter D, Switzer WM, Heneine W, Kirchhoff F, Delsuc F, Telenti A, Benkirane M. 2012. Evolutionary and functional analyses of the interaction between the myeloid restriction factor SAMHD1 and the lentiviral Vpx protein. Cell Host Microbe 11:205-217. http://dx.doi.org/10.1016/j.chom.2012.01.007.
25. Lim ES, Malik HS, Emerman M. 2010. Ancient adaptive evolution of tetherin shaped the functions of Vpu and Nef in human immunodeficiency virus and primate lentiviruses. J Virol 84:7124-7134. http://dx.doi.org/10.1128/JVI.00468-10.
26. McNatt MW, Zang T, Hatziioannou T, Bartlett M, Fofana IB, Johnson WE, Neil SJ, Bieniasz PD. 2009. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog 5:e1000300. http://dx.doi.org/10.1371/journal.ppat.1000300.
27. Sawyer SL, Emerman M, Malik HS. 2004. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol 2:E275. http://dx.doi.org/10.1371/journal.pbio.0020275.
28. Sawyer SL, Wu LI, Emerman M, Malik HS. 2005. Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain. Proc Natl Acad Sci U S A 102:2832-2837. http://dx.doi.org /10.1073/pnas.0409853102.
29. Sauter D, Schindler M, Specht A, Landford WN, Munch J, Kim KA, Votteler J, Schubert U, Bibollet-Ruche F, Keele BF, Takehisa J, Ogando Y, Ochsenbauer C, Kappes JC, Ayouba A, Peeters M, Learn GH, Shaw G, Sharp PM, Bieniasz P, Hahn BH, Hatziioannou T, Kirchhoff F. 2009. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 6:409-421. http://dx.doi.org/10.1016/j.chom.2009.10.004.
30. Chowers MY, Spina CA, Kwoh TJ, Fitch NJ, Richman DD, Guatelli JC. 1994. Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene. J Virol 68:2906-2914.
31. Rosa A, Chande A, Ziglio S, De Sanctis V, Bertorelli R, Goh SL, McCauley SM, Nowosielska A, Antonarakis SE, Luban J, Santoni FA, Pizzato M. 2015. HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation. Nature 526:212-217. http://dx.doi.org/10.1038/nature15399.
32. Usami Y, Wu Y, Gottlinger HG. 2015. SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef. Nature 526:218-223. http: //dx.doi.org/10.1038/nature15400.
33. Pond SL, Scheffler K, Gravenor MB, Poon AF, Frost SD. 2010. Evolutionary fingerprinting of genes. Mol Biol Evol 27:520-536. http://dx.doi.org/10.1093/molbev/msp260.
34. Murrell B, Moola S, Mabona A, Weighill T, Sheward D, Kosakovsky Pond SL, Scheffler K. 2013. FUBAR: a fast, unconstrained Bayesian approximation for inferring selection. Mol Biol Evol 30:1196-1205. http: //dx.doi.org/10.1093/molbev/mst030.
35. Rosenbloom KR, Armstrong J, Barber GP, Casper J, Clawson H, Diekhans M, Dreszer TR, Fujita PA, Guruvadoo L, Haeussler M, Harte RA, Heitner S, Hickey G, Hinrichs AS, Hubley R, Karolchik D, Learned K, Lee BT, Li CH, Miga KH, Nguyen N, Paten B, Raney BJ, Smit AF, Speir ML, Zweig AS, Haussler D, Kuhn RM, Kent WJ. 2015. The UCSC Genome Browser database: 2015 update. Nucleic Acids Res 43:D670-D681. http://dx.doi.org/10.1093/nar/gku1177.
36. Yang Z, Nielsen R. 2002. Codon-substitution models for detecting molecular adaptation at individual sites along specific lineages. Mol Biol Evol 19:908-917. http://dx.doi.org/10.1093/oxfordjournals.molbev.a004148.
37. Price AJ, Marzetta F, Lammers M, Ylinen LM, Schaller T, Wilson SJ, Towers GJ, James LC. 2009. Active site remodeling switches HIV specificity of antiretroviral TRIMCyp. Nat Struct Mol Biol 16:1036-1042. http: //dx.doi.org/10.1038/nsmb.1667.